Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Novartis’ Kisqali® Receives FDA Approval as First-Line Treatment for HR+/HER2- Metastatic Breast Can

americanpharmaceuticalreviewMarch 14, 2017

Tag: FDA , Novartis

PharmaSources Customer Service